First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report
Authors:
Open Access
- 16 April 2025
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1564774
Abstract
Background: Chimeric antigen receptor T (CAR-T) cells targeting B-cell maturation antigen (BCMA) have been used as an effective therapy against relapsed/refractory multiple myeloma (MM). However, the relapse rates in these patients are still high, which may be related to the poor quality of T cells after multiple chemotherapies. The case reported here demonstrated the effectiveness and safety of first-line anti-BCMA CAR-T cell therapy for high-risk MM patients, even in frailty with multiple comorbidities.Case presentation: A 75-year-old woman was diagnosed with biclonal gammopathy and high-risk MM with extramedullary mass in the right caput femoris. The patient was fragile with multiple comorbidities, including pneumonia, left lower limb deep venous thrombosis, and epilepsy secondary to cerebral hemorrhage. Considering the patient’s fragility and comorbidities, commercial equecabtagene autoleucel, a fully human anti-BCMA CAR-T cells, as first-line CAR-T cell therapy, was proposed and accepted by the patient and her family. After one cycle of bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen), she reached very good partial response (VGPR). Then her leukapheresis was performed, and the harvested cells were sent to the manufacturer for preparation. After lymphodepletion was performed using fludarabine and cyclophosphamide (FC) chemotherapy, her equecabtagene autoleucel was transfused. On day 21 after infusion, she achieved stringent complete remission (sCR) with minimal residual disease (MRD) negativity without severe toxicity. The CAR-T cells/CD3+ T cell ratio gradually increased, reaching a maximum of 54.97% on day 14, and gradually decreased, remaining at 0.03% on the 153rd day. The patient received right hip replacement plus pelvic lesion curettage 7 months after CAR-T transfusion due to pain in her right hip, but no MM cells were found in postoperative pathology. Hitherto, her deep remission persisted for 12 months without any maintenance therapy.Conclusion: First-line anti-BCMA CAR-T cell therapy is effective and safe for high-risk MM patients, even in fragile patients with multiple comorbidities.Keywords
This publication has 29 references indexed in Scilit:
- Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple MyelomaJAMA Oncology, 2024
- Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myelomaMolecular Therapy, 2024
- Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple MyelomaTransplantation and Cellular Therapy, 2023
- Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyTransplantation and Cellular Therapy, 2023
- Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple MyelomaTransplantation and Cellular Therapy, 2023
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2022
- Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustionEBioMedicine, 2022
- Diagnosis and Management of Multiple MyelomaJAMA, 2022
- Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An UpdateDrugs, 2017
- Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyAnnals of Hematology, 2017